Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 6/14/2018 |
| Start Date: | February 2007 |
| End Date: | January 2017 |
Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC to Problematic Gram-negative Organisms
The isolate samples will be collected over a period of one year once IRB approval has been
obtained. These isolates were collected as part of the patient's clinical care and once all
clinical testing is complete, all isolates will be discarded. The honest broker of our area
will collect the isolates and deidentify all information once all clinical testing is
complete. The isolates will be obtained from the microbiology lab.
obtained. These isolates were collected as part of the patient's clinical care and once all
clinical testing is complete, all isolates will be discarded. The honest broker of our area
will collect the isolates and deidentify all information once all clinical testing is
complete. The isolates will be obtained from the microbiology lab.
The study will collect two hundred pseudomonas and 20 acinetobacter baumanti consecutive
bacterial isolates from microbiology. These isolates are collected as part of the patient's
clinical care and are discarded once all clinical testing is complete. The honest broker will
obtain these samples after all clinical testing is complete. All isolates will be
deidentified. These isolates will be tested using standardized susceptibility methods for
meropenem and imipenem. The activity of doripenem, a carbapenem currently being studied, and
arbekacin an aminoglycoside, will also be tested. The honest broker will also collect limited
patient data including underlying condition, presence of a solid organ transplant, ward
location, and antibiotic history over the three months prior to organism isolation. For
resistant isolates found, analytical and molecular techniques will be performed to determine
the mechanisms of resistance and whether resistant isolates are coming from a single
source/being transmitted from person to person.
bacterial isolates from microbiology. These isolates are collected as part of the patient's
clinical care and are discarded once all clinical testing is complete. The honest broker will
obtain these samples after all clinical testing is complete. All isolates will be
deidentified. These isolates will be tested using standardized susceptibility methods for
meropenem and imipenem. The activity of doripenem, a carbapenem currently being studied, and
arbekacin an aminoglycoside, will also be tested. The honest broker will also collect limited
patient data including underlying condition, presence of a solid organ transplant, ward
location, and antibiotic history over the three months prior to organism isolation. For
resistant isolates found, analytical and molecular techniques will be performed to determine
the mechanisms of resistance and whether resistant isolates are coming from a single
source/being transmitted from person to person.
Inclusion Criteria:
- Samples" for the purpose of this study are Gram negative bacteria in a Petri dish of
growth media.
We found this trial at
2
sites
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
Click here to add this to my saved trials
Click here to add this to my saved trials